Organon Launches Publically Accessible Website on Its Clinical Trials
Today Organon announces the launch of a clinical trial website - www.organon-trials.com - that will provide results of the company’s completed trials and a registry of ongoing trials.
June 16, 2005, Oss, The Netherlands - Today Organon announces the launch of a clinical trial website - www.organon-trials.com - that will provide results of the company's completed trials and a registry of ongoing trials. The website will further increase the transparency of the clinical trials Organon sponsors. The site is freely accessible without restriction.
"Organon is committed to provide transparency about the trials we conduct by making this information available in the public domain. We are pleased to be one of the first pharmaceutical companies to introduce such an initiative," commented Dr Henk Jan Out, Head of Global Clinical Development at Organon. With this action, Organon follows the recommendation from the joint pharmaceutical company associations and editors of the major medical journals.
The clinical trial registry contains information on all phase III and beyond trials currently taking place.1 This includes a unique identifying number, purpose of the study, study type and design, eligibility criteria, target number of patients, countries where the study is running and contact information.
The clinical trial results section will summarize the findings of the clinical trials that have been performed with currently available major products of Organon. The number will grow as additional older trials are added. In addition, once trials posted on the registry have been completed and marketing approval gained in one country, the results from all studies - including those preceding the phase III trials - will be posted in the clinical trial results section. Similarly, Organon will also report results of earlier trials when already marketed drugs have been approved in new indications.
Both the registry and results sections provide scientific, non-promotional and comprehensive summaries of clinical trials in a consistent format irrespective of whether the results may be viewed as positive or negative for the medicine concerned. The site will be updated regularly to ensure the information is accurate and up-to-date.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
